Polycystic kidney disease is inherited. Fluid-filled cysts form and multiply, and over decades they crowd out the tissue that does the filtering.
If a parent has it, each child has a fifty percent chance. That fact makes this page matter as much to your family as to you.
What patients are usually told, and what is actually true
The old answer was that polycystic kidney disease is genetic, nothing changes it, and you wait.
That has not been true for years, and it is still what most patients hear.
Two things alter the course. Rigorous early blood pressure control — in your thirties, before eGFR has moved at all — appears to slow kidney growth. And tolvaptan, the first drug shown to slow progression, is now available for patients at high risk of rapid decline.
Neither works well if you arrive late. Tolvaptan is most valuable before substantial function is lost. Blood pressure control matters most in the decade before anything shows up on a lab report.
The window for the interventions that work opens long before you feel sick, and closes quietly.
Whether you are a tolvaptan candidate is a specific question
Not everyone should take it. It causes substantial thirst and frequent urination, requires liver monitoring, and is reserved for patients at high risk of rapid progression.
Identifying those patients is real work: total kidney volume relative to age, the rate of eGFR decline, family history, and genotype. Most patients with polycystic kidney disease have never had their total kidney volume measured, which means the question was never actually asked.
Board-certified nephrology at Remix Medical in Houston. Call (713) 597-5131 or book online.
What it does over time
The kidneys enlarge, sometimes dramatically, as cysts accumulate.
High blood pressure usually arrives first, often in the thirties, before kidney function declines at all. It comes from cyst expansion activating the renin-angiotensin system — which is why it appears so early and why controlling it early matters so much.
Roughly half of people with the autosomal dominant form reach kidney failure, typically between fifty and seventy. The other half never do. Which group you are in depends substantially on genotype and on kidney volume relative to your age, and both can be assessed.
Genotype is not academic
Testing distinguishes PKD1 from PKD2. PKD1, particularly truncating mutations, reaches kidney failure roughly two decades earlier than PKD2.
Two decades. That changes surveillance intervals, drives the tolvaptan decision, and matters enormously for your siblings, your children, and reproductive planning.
Screening an at-risk child is a genuinely hard question — insurance implications, and what it does to a young person's sense of their own future. It deserves a conversation, not a reflex.
| Factor | Lower risk | Higher risk |
|---|---|---|
| Genotype | PKD2 | PKD1 (truncating mutation) |
| Kidney size for age | Smaller | Enlarged (high Mayo imaging class) |
| Blood pressure | Controlled, later onset | High before age 35 |
| Protein in urine | Minimal | Elevated |
Not only a kidney disease
Brain aneurysms occur at several times the general rate. Screening is warranted with a family history of aneurysm or hemorrhage, before major surgery, or in high-risk occupations. Not everyone needs it, and the decision deserves real discussion rather than a reflex in either direction.
Liver cysts are very common and usually harmless.
Mitral valve prolapse, diverticulosis, abdominal wall hernias.
Kidney stones in about one in five.
Cyst hemorrhage and cyst infection both occur and both hurt considerably.
What we do
Establish your trajectory rather than a single eGFR — the rate of decline is what predicts your future.
Measure total kidney volume, so the tolvaptan question is answered rather than deferred.
Control blood pressure aggressively and early, with the agents that block the renin-angiotensin system.
Genetic testing where it changes the plan, which is more often than people expect.
Generous fluid to suppress vasopressin. Sodium restriction. No NSAIDs. No smoking.
Caffeine gets mentioned constantly. The evidence is weak and moderate intake is fine.
Planning, early
If kidney failure is coming, it is visible decades out. That is the advantage of this disease over most others.
A transplant evaluation can begin before dialysis ever starts, and a preemptive transplant — before the first dialysis session — produces better outcomes than one after.
If you have polycystic kidney disease, or a parent or sibling does, come early. The interventions that change the course work best before you feel anything.
Call (713) 597-5131 or book online.